The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 16)
-
AC Immune SA (NASDAQ: ACIU) ( announced clinical trial update for its Alzheimer's vaccine candidate)
-
argenx SE – ADR (NASDAQ: ARGX)
-
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
-
Castle Biosciences Inc (NASDAQ: CSTL)
-
Dynavax Technologies Corporation (NASDAQ: DVAX)(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant)
-
Heat Biologics Inc (NASDAQ: HTBX)
-
Novavax, Inc. (NASDAQ: NVAX)
-
Qiagen NV (NYSE: QGEN)( Thermo Fisher Scientific Inc. (NYSE: TMO) announced a sweetened offer to buy the company)
-
Quest Diagnostics Inc (NYSE: DGX)
-
Otonomy Inc (NASDAQ: OTIC)
-
Principia Biopharma Inc (NASDAQ: PRNB)(reacted to buyout rumors)
-
Relay Therapeutics Inc (NASDAQ: RLAY) (jumped 75.25% on its debut)
-
Sanofi SA (NASDAQ: SNY) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia)
-
TIZIANA LF SCIE/S ADR (NASDAQ: TLSA)
-
West Pharmaceutical Services Inc. (NYSE: WST)
Down In The Dumps
(Biotech Stocks Hitting 52-week Lows July 16)
-
Avidity Biosciences Inc (NASDAQ: RNA)
-
Legend Biotech Corp (NASDAQ: LEGN)
-
Nkarta Inc (NASDAQ: NKTX) (IPOed last Friday)
-
Repare Therapeutics Inc (NASDAQ: RPTX)
-
Tricida Inc (NASDAQ: TCDA) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic acidosis treatment candidate)
Stocks In Focus PhaseBio Doses First Patient In Potentially Pivotal Trial of PB1046 For COVID-19
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) said it has dosed the first patient in a potentially pivotal Phase 2 clinical trial, dubbed VANGARD, to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome, or ARDS.
PB1046 is a novel, once-weekly, subcutaneously-injected VIP receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems, having anti-inflammatory, antifibrotic and potent bronchodilatory and immunomodulatory effects in the respiratory system.
The stock advanced 10.21% to $5.18 in after-hours trading.
Applied DNA Reports Positive Preclinical Data For DNA Vaccine Candidates
Applied DNA Sciences Inc (NASDAQ: APDN) announced linear-DNA forms of COVID-19 vaccine candidates under development by partner Takis Biotech and manufactured by it yielded strong antibody and T-cell responses even at very low doses of linear DNA, raising the potential of effective dosing empowering global utility.